Skip to main content
. 2022 May 20;19(8):533–550. doi: 10.1038/s41575-022-00608-8

Table 5.

Antiviral combinations recommended by the EASL in special populations in 2021

Population Grazoprevir–elbasvir Glecaprevir–pibrentasvir Sofosbuvir–velpatasvir Sofosbuvir–velpatasvir–voxilaprevir
NS5A-inhibitor experienced No No No 12 weeks
Subtype 1l, 4r, 3b, 3g, 6u, 6v or any other subtype naturally harbouring one or several NS5A RASs No Efficacy unknown Efficacy unknown 12 weeks
Decompensated liver cirrhosis No No 12 weeks + RBVa No
End-stage renal disease Recommended Recommended Possible Possible

Data from ref.5. EASL, European Association for the Study of the Liver; NS5A, nonstructural protein 5A; RAS, resistance-associated substitution; RBV, ribavirin. aIf RBV is not tolerated, 24 weeks of treatment is recommended.